February 3, 1987
Liberace, the flamboyant showman who parlayed a white piano and candelabra into a show business legend, was near death as family and friends gathered at his Palm Springs home, his publicist said. "It looks like death is imminent," said Denise Collier, press agent for the 67-year-old entertainer. "It's going to be within the next 24 to 48 hours." Collier described Liberace as being in a semi-conscious state suffering from pernicious anemia, complicated by advanced emphysema and heart disease.
September 26, 2009 |
Supreme Court Justice Ruth Bader Ginsburg, who had cancer surgery earlier this year, made a quick return to work after feeling ill at the office and spending Thursday night in a hospital as a precaution. The 76-year-old justice was released from Washington Hospital Center in the morning and was at her desk by early afternoon, the court said. Ginsburg became lightheaded in her office Thursday afternoon after receiving treatment for anemia. Although she was found to be stable after an examination, the court said, she was taken to the hospital as a precaution.
June 23, 1989
Drug Reimbursements Approved: The federal Health Care Financing Administration has agreed to reimburse kidney dialysis centers when patients use Amgen Inc.'s new Epogen drug, retroactive to June 1. Epogen is the brand name for erythropoietin, a protein developed by the Thousand Oaks biotechnology company that is used to treat chronic anemia by stimulating production of red blood cells. Amgen said the U.S. will reimburse about 80% of a patient's treatment costs, with states covering the balance.
December 8, 2007 |
Shares of Amgen Inc. fell the most in seven months Friday after the biotech company said it might revise the safety information on its biggest product, anemia drug Aranesp. Amgen fell $3.05, or 5.5%, to $52.10, the most since May 10, when a Food and Drug Administration panel suggested new restrictions in prescribing information for the anemia drug.
May 10, 2006 |
Amgen Inc. said the U.S. International Trade Commission would investigate a complaint seeking to block Roche Holding Ltd. of Switzerland from importing a rival anemia drug. Roche's experimental drug Cera, which would compete with Amgen's Aranesp and Epogen medicines, violates six U.S. patents, Thousand Oaks-based Amgen said. Amgen also is suing Roche in U.S. court to block it from introducing Cera. At a hearing in Boston today, Roche will ask a federal judge to throw out that case.
April 28, 1990 |
Amgen, a biotechnology company in Thousand Oaks, lost a round Friday in its complex legal fight with rival Genetics Institute over U.S. marketing rights for a new anti-anemia drug. Genetics Institute, based in Cambridge, Mass., and its partner, Chugai Pharmaceutical Co. of Japan, said a U.S. Appeals Court dismissed Amgen's appeal of an order by the International Trade Commission that would permit Genetics Institute and Chugai to import their version of the drug from Japan to the U.S.
CALIFORNIA | LOCAL
January 25, 1995
A sickle cell anemia self-help organization has appealed for $1,000 to bury a 1-year-old boy who died of the disease. "Whatever it takes to get this baby out of the morgue, that is what we're going to do," said Sister Somayah, an Islamic spiritualist representing Crescent Alliance Self-Help for Sickle Cell. The coroner's office "won't release the body until all arrangements have been made," Somayah said, adding that the organization already has raised $500 for the burial. She said her group hopes a cemetery will volunteer to take the body, even if there is only a $500 down payment.
July 8, 2006 |
An administrative law judge has allowed drug maker Roche Holding Ltd. to continue to import an experimental anemia drug at the center of a patent fight between Roche and Amgen Inc., the companies said Friday. The judge at the U.S. International Trade Commission has determined that Roche can import its experimental drug peg-EPO, also known as Cera, under an exception for clinical trials, the companies said.
February 4, 1989 |
Amgen Inc., a Thousand Oaks biotechnology company already embroiled in patent lawsuits over its new anti-anemia drug, has been hit with another suit from its own marketing partner, consumer products giant Johnson & Johnson. Ortho Pharmaceutical, a Johnson & Johnson unit, asked a federal court in Delaware to block Amgen's effort to get federal approval for the drug and to begin marketing it.